Pacira BioSciences, Inc. (PCRX)Healthcare | Drug Manufacturers - Specialty & Generic | Brisbane, United States | NasdaqGS
25.54 USD
+0.06
(0.235%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 25.54 |
Hot Take ↕ | July 11, 2026, 4:07 a.m. EDT
The immediate outlook is cautiously optimistic, driven by a distinct shift in sentiment where traders are buying calls at strikes significantly above the current price while simultaneously hedging against a crash via expensive put options. This divergence suggests a belief in a potential catalyst or recovery, though the market remains deeply anxious about a sharp drop. Long-term, the picture is mixed. While the company recently turned the corner with a positive year-over-year gain, the broader nine-year trajectory remains a structural decline of roughly 37%. The market has punished the stock heavily, leaving it trading at a massive trailing P/E of 196x, which reflects extreme skepticism about future earnings power rather than a margin of safety. The balance sheet is technically healthy with low debt, but the lack of a dividend and the history of volatile performance prevent a top-tier 'buy and hold' rating. It is a turnaround story that has finally stopped bleeding, but the road to restoring full confidence is long. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.040467 |
| AutoETS | 0.040467 |
| AutoTheta | 0.040979 |
| MSTL | 0.042591 |
| MSTL_115 | 0.046715 |
| MSTL_70 | 0.053157 |
| MSTL_70_115 | 0.055994 |
Forecast horizon: 60 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 1.48 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.079 |
| Excess Kurtosis | -1.40 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 62.882 |
| Revenue per Share | 17.045 |
| Market Cap | 1,004,945,984 |
| Trailing P/E | 196.46 |
| Forward P/E | 7.00 |
| Beta | 0.27 |
| Profit Margins | 0.70% |
| Website | https://www.pacira.com |
As of July 11, 2026, 4:07 a.m. EDT: Speculators are positioning for a moderate upside move, evidenced by heavy open interest in out-of-the-money calls (strikes $30 and $40) relative to puts. However, the implied volatility surface shows a significant skew, with put IV nearly 2.5x higher than call IV, indicating deep fear regarding downside protection despite the bullish positioning.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.09309304 |
| Address1 | 2,000 Sierra Point Parkway |
| Address2 | Suite 900 |
| All Time High | 121.95 |
| All Time Low | 6.16 |
| Ask | 32.43 |
| Ask Size | 2 |
| Audit Risk | 1 |
| Average Analyst Rating | 2.3 - Buy |
| Average Daily Volume10 Day | 506,070 |
| Average Daily Volume3 Month | 521,101 |
| Average Volume | 521,101 |
| Average Volume10Days | 506,070 |
| Beta | 0.271 |
| Bid | 18.3 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 16.634 |
| City | Brisbane |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 25.54 |
| Current Ratio | 4.734 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 25.89 |
| Day Low | 25.255 |
| Debt To Equity | 62.882 |
| Display Name | Pacira BioSciences |
| Earnings Call Timestamp End | 1,777,581,000 |
| Earnings Call Timestamp Start | 1,777,581,000 |
| Earnings Growth | -0.3 |
| Earnings Quarterly Growth | -0.394 |
| Earnings Timestamp | 1,777,579,200 |
| Earnings Timestamp End | 1,777,579,200 |
| Earnings Timestamp Start | 1,777,579,200 |
| Ebitda | 121,288,000 |
| Ebitda Margins | 0.16504999 |
| Enterprise To Ebitda | 10.009 |
| Enterprise To Revenue | 1.652 |
| Enterprise Value | 1,213,944,960 |
| Eps Current Year | 2.87698 |
| Eps Forward | 3.64778 |
| Eps Trailing Twelve Months | 0.13 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 23.752 |
| Fifty Day Average Change | 1.7880001 |
| Fifty Day Average Change Percent | 0.07527787 |
| Fifty Two Week Change Percent | 9.309303 |
| Fifty Two Week High | 27.64 |
| Fifty Two Week High Change | -2.0999985 |
| Fifty Two Week High Change Percent | -0.07597679 |
| Fifty Two Week Low | 18.8 |
| Fifty Two Week Low Change | 6.7400017 |
| Fifty Two Week Low Change Percent | 0.35851073 |
| Fifty Two Week Range | 18.8 - 27.64 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,296,743,400,000 |
| Float Shares | 33,707,399 |
| Forward Eps | 3.64778 |
| Forward P E | 7.001519 |
| Free Cashflow | 98,615,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 825 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.79335 |
| Gross Profits | 583,008,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.017690001 |
| Held Percent Institutions | 1.15562 |
| Implied Shares Outstanding | 39,347,924 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California. |
| Long Name | Pacira BioSciences, Inc. |
| Market | us_market |
| Market Cap | 1,004,945,984 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_27508 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 5,138,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,002,191,624 |
| Number Of Analyst Opinions | 6 |
| Open | 25.395 |
| Operating Cashflow | 142,215,008 |
| Operating Margins | 0.02607 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 11.21 |
| Phone | 650 242 8052 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 25.54 |
| Post Market Time | 1,783,981,117 |
| Previous Close | 25.48 |
| Price Eps Current Year | 8.877364 |
| Price Hint | 2 |
| Price To Book | 1.5354093 |
| Price To Sales Trailing12 Months | 1.3675265 |
| Profit Margins | 0.00699 |
| Quick Ratio | 3.014 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.33333 |
| Region | US |
| Regular Market Change | 0.0600014 |
| Regular Market Change Percent | 0.235484 |
| Regular Market Day High | 25.89 |
| Regular Market Day Low | 25.255 |
| Regular Market Day Range | 25.255 - 25.89 |
| Regular Market Open | 25.395 |
| Regular Market Previous Close | 25.48 |
| Regular Market Price | 25.54 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 437,576 |
| Return On Assets | 0.013459999 |
| Return On Equity | 0.00708 |
| Revenue Growth | 0.05 |
| Revenue Per Share | 17.045 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 39,347,924 |
| Shares Percent Shares Out | 0.1674 |
| Shares Short | 6,587,848 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 6,596,044 |
| Short Name | Pacira BioSciences, Inc. |
| Short Percent Of Float | 0.24209999 |
| Short Ratio | 13.85 |
| Source Interval | 15 |
| State | CA |
| Symbol | PCRX |
| Target High Price | 38.0 |
| Target Low Price | 23.0 |
| Target Mean Price | 29.66667 |
| Target Median Price | 28.5 |
| Total Cash | 202,180,000 |
| Total Cash Per Share | 5.138 |
| Total Debt | 411,179,008 |
| Total Revenue | 734,864,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.13 |
| Trailing P E | 196.46155 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 23.37795 |
| Two Hundred Day Average Change | 2.1620502 |
| Two Hundred Day Average Change Percent | 0.092482455 |
| Type Disp | Equity |
| Volume | 437,576 |
| Website | https://www.pacira.com |
| Zip | 94,005 |